Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Fnct Biotech Inc. is currently active in the Biotechnology & Pharmaceuticals technology area, with 2 pending office actions. This level of activity suggests a focused approach to protecting their innovations in biological or pharmaceutical research. The prosecution workload is shared between 2 distinct examiners, which indicates that each pending matter is receiving individual technical scrutiny.
The applications are being processed in 2 distinct art units. This distribution suggests that the company's technology may fall into different specialized categories within the broader biotechnology field. For practitioners, this means that the prosecution strategy must be sensitive to the specific examination standards and precedents of each art unit involved.
CHERNYSHEV, OLGA N is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. Since the workload is distributed across different examiners and art units, the prosecution risk is not concentrated in a single area. Success will require a tailored approach for each application that considers the specific preferences of the assigned examiner and the standards of the art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
| XIE, XIAOZHEN | 1 | 56.7% | +65.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18689582 | CSF3R AS BIOMARKER AND THERAPEUTIC TARGET FOR PULMONARY FIBROSIS | CHERNYSHEV, OLGA N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016752 | METHOD FOR SCREENING COLORECTAL CANCER METASTASIS INHIBITOR | XIE, XIAOZHEN | 71d |
| 18689582 | CSF3R AS BIOMARKER AND THERAPEUTIC TARGET FOR PULMONARY FIBROSIS | CHERNYSHEV, OLGA N | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18689582 | CSF3R AS BIOMARKER AND THERAPEUTIC TARGET FOR PULMONARY FIBROSIS | CHERNYSHEV, OLGA N | 1675 | §103§112 | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18016752 | METHOD FOR SCREENING COLORECTAL CANCER METASTASIS INHIBITOR | XIE, XIAOZHEN | 1674 | §102 | Final Rejection | 71d | Pending | Jan 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFnct Biotech Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Olga N Chernyshev has the most, with 1 of Fnct Biotech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
